C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.165 AUD -0.43% Market Closed
Market Cap: 129.5m AUD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+11%
Revenue
Forecast
+6%
Operating Income
Forecast
N/A
Net Income
Forecast
+16%

Wall Street
Price Targets

CYC Price Targets Summary
Cyclopharm Ltd

Wall Street analysts forecast CYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYC is 2.754 AUD with a low forecast of 2.727 AUD and a high forecast of 2.835 AUD.

CYC Lowest Forecast
Wall Street Target
2.727 AUD
134% Upside
CYC Average Forecast
Wall Street Target
2.754 AUD
136% Upside
CYC Highest Forecast
Wall Street Target
2.835 AUD
143% Upside
Lowest
Price Target
2.727 AUD
134% Upside
Average
Price Target
2.754 AUD
136% Upside
Highest
Price Target
2.835 AUD
143% Upside
Cyclopharm Ltd Competitors:
Price Targets
ABT
Abbott Laboratories
10% Upside
ATRC
AtriCure Inc
85% Upside
300633
SonoScape Medical Corp
33% Upside
ELN
El En SpA
37% Upside
ABT
Abbott Laboratories
10% Upside
ATRC
AtriCure Inc
85% Upside
300633
SonoScape Medical Corp
33% Upside
ELN
El En SpA
37% Upside
ISRG
Intuitive Surgical Inc
16% Upside
GKOS
Glaukos Corp
88% Upside
EUZ
Eckert & Ziegler Strahlen und Medizintechnik AG
7% Upside
SHL
Siemens Healthineers AG
34% Upside

Revenue
Forecast

Revenue Estimate
Cyclopharm Ltd

For the last 8 years the compound annual growth rate for Cyclopharm Ltd's revenue is 8%. The projected CAGR for the next 3 years is 50%.

8%
Past Growth
50%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Cyclopharm Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Cyclopharm Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
What are analyst estimates?

See Also

Summary
CYC intrinsic value, competitors valuation, and company profile.
DCF Valuation
CYC stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CYC stock valuation using valuation multiples.
Wall Street Estimates
CYC price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CYC stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CYC's stock price target?
Price Target
2.754 AUD

According to Wall Street analysts, the average 1-year price target for CYC is 2.754 AUD with a low forecast of 2.727 AUD and a high forecast of 2.835 AUD.

What is Cyclopharm Ltd's Revenue forecast?
Projected CAGR
50%

For the last 8 years the compound annual growth rate for Cyclopharm Ltd's revenue is 8%. The projected CAGR for the next 3 years is 50%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 251,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.